GoodRx Holdings

GoodRx Holdings, Inc. operates a consumer-focused digital healthcare platform. The firm offers information and tools to help consumers compare prices for prescription drugs. It operates applications and websites that provide prices and discounts at local and mail-order pharmacies. The company was founded by in Trevor Bezdek and Douglas Hirsch Joseph in September 2015 and is headquartered in Santa Monica, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GoodRx reports Q4 revenue decline but anticipates growth opportunities

GoodRx's Q4 2022 performance showed a decline in revenue but improvements in adjusted EBITDA. The company's focus on deepening relationships, increasing savings, and leveraging data presents strengths. Challenges include financial impacts from the grocer issue and decisions on revenue streams. Opportunities lie in non-grocery retailers, pharma manufacturer solutions, and sales optimization.

GoodRx reports strong Q1 performance and anticipates growth opportunities

GoodRx's Q1 performance reflects growth and positive outlook for managed solutions segment, despite challenges in revenue moderation and deal timelines.
The company's strengths lie in its strong foundation, talented team, and unique marketplace value proposition, with opportunities for further growth and innovation.
Challenges include potential revenue impact from program moderation and deal delays, but regulatory proposals are not expected to significantly affect business operations.
Overall, GoodRx remains focused on driving volume growth, maintaining market leadership, and providing affordable prescriptions to consumers.

GoodRx exceeds Q2 guidance, focuses on growth and partnerships

GoodRx's Q2 2023 earnings call showcased strong financial performance, exceeding guidance and reporting net income driven by a release of valuation allowance.
The company's focus on growth, profitability, and strategic realignment positions it well for compounding growth in 2024 and beyond, emphasizing proactive retail partnerships and efficient customer service strategies.
While challenges in deprioritizing certain solutions and balancing marketing spend efficiency exist, opportunities in optimizing retailer partnerships, leveraging data analytics, and attracting new members without incremental spend are key for future success.
Overall, GoodRx's innovative approach, unique value proposition, and financial and operational strengths highlight its resilience and potential for sustained growth and profitability.

GoodRx reports revenue growth and eyes pharma solutions expansion

GoodRx reported solid Q3 performance with revenue growth and strong cash generation, focusing on margin improvement and bottom-line profitability.
Despite challenges in subscription revenue and one-time payments, the company is eyeing growth opportunities in ISP, pharma solutions, and marketing efforts.
Analyst questions addressed key areas like retail stability, revenue growth expectations, and margin dynamics, indicating investor interest in future prospects.
GoodRx's strategic focus on expanding services, enhancing pricing strategies, and market access programs positions it for continued growth and value creation.

GoodRx exceeds Q4 expectations, eyes growth through strategic initiatives

GoodRx's Q4 '23 performance reflects strong financials, operational resilience, and strategic focus on growth initiatives.
The company's success in saving consumers billions and expanding market reach positions it well for future opportunities.
Challenges such as system issues and market competition require ongoing attention and strategic planning.
Opportunities in scaling solutions, targeted marketing, and strategic partnerships can drive sustained growth and market leadership.

GoodRx reports solid Q1 performance, eyes margin expansion opportunities

GoodRx's Q1 2024 performance showcased revenue growth and strong EBITDA margins, supported by strategic capital deployment and cash reserves.
Challenges include PTR per MAC decline and addressing analyst inquiries on ISP growth and margin concerns.
Opportunities lie in upcoming Analyst Day insights, ISP performance enhancements, and driving margin expansion through operational efficiencies.
Overall, GoodRx anticipates sustained growth, margin improvement, and continued ISP expansion throughout the year.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GoodRx Holdings, Inc. engages in the business of a consumer-focused digital healthcare platform. The firm offers consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. The company was founded by Trevor Bezdek and Douglas Joseph Hirsch in September 2011 and is headquartered in Santa Monica, CA.

GoodRx addresses many challenges in the U.S. healthcare space. GoodRx's tech-enabled solutions are proving to be an immense value-add as their platforms have built great trust with their consumers.

GoodRx: Navigating High Customer Acquisition Costs

GoodRx will have to pay a $1.5 million fine as part of a proposed settlement with the Federal Trade Commission if it gets approved by a federal court.

GoodRx to pay $1.5 million fine as part of FTC settlement

The Federal Trade Commission (FTC) has taken the first enforcement action under its Health Breach Notification Rule. The proposed order bars digital health platform GoodRX from sharing consumers' health information for advertising and fines the firm $1.

FTC and GoodRX Settle Complaint Around Health Breach Notification Rule

In a first-of-its-kind enforcement, the Federal Trade Commission has imposed a $1.5 million penalty on telehealth and prescription drug discount provider GoodRx Holdings Inc. for sharing users' personal health data with Facebook, Google and other third parties without their consent.

FTC fines GoodRx for unauthorized sharing of users' health data

Under a proposed FTC order, GoodRX would be barred from sharing user health data for advertising purposes.

FTC Accuses GoodRX of Sharing User Data Without Consent

The popular drug discount app deceptively shared details on users' illnesses and medicines with ad firms, regulators said in a legal complaint.

GoodRx Leaked User Health Data to Facebook and Google, F.T.C. Says

Online pharmacy GoodRx has agreed to pay $1.5 million in civil penalties for years of sharing the health information of consumers with third parties like Facebook, Google, and Criteo for advertising purposes, the Federal Trade Commission said Wednesday.

FTC slaps online pharmacy GoodRx for sharing users' health data with Facebook and Google

SANTA MONICA, Calif.--( BUSINESS WIRE )--At GoodRx, protecting our users' privacy is one of our most important priorities. We are thoughtful and disciplined about what information we gather and how and why we use it.

GoodRx Response to FTC Settlement

U.S. healthcare firm GoodRx Holdings has agreed to pay $1.5 million to settle allegations that it failed to notify customers that it shared personal health information with Alphabet's Google, Meta's Facebook and others, the Federal Trade Commission said on Wednesday.

GoodRx pays $1.5 million to settle health privacy allegations

SANTA MONICA, Calif.--( BUSINESS WIRE )--GoodRx Holdings Inc. (Nasdaq: GDRX), a leading digital healthcare platform, today announced it will release its fourth quarter and full year 2022 financial results after U.S. markets close on Tuesday, February 28, 2023. GoodRx management will also hold a conference call and webcast that day at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss the results and the Company's business outlook.

GoodRx Announces Date for Fourth Quarter and Full Year 2022 Earnings Release and Conference Call

Fiverr

Robinhood

Redfin

Roku

Block

Wish

There are many reasons to remain bullish on technology stocks. Companies such as Apple (NASDAQ: AAPL ) and Alphabet (NASDAQ: GOOGL ) remain extremely well-run, hugely profitable enterprises.

7 Sorry Tech Stocks to Sell in February Before It's Too Late

GoodRX addresses the challenges that the US healthcare industry is facing. Given that the industry has a large TAM, I think GDRX can continue to grow over the long term.

GoodRx: Strong Value Proposition Enables Long-Term Growth

PayPal

AT&T

These investments could make the most of your money next year, whether your focus is on growth or dividends.

Where to Invest $500 in 2023: 3 Stocks That Could Be Winners

SANTA MONICA, Calif.--( BUSINESS WIRE )--GoodRx Holdings, Inc. (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform, today announced that executives from the Company will be presenting at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 11, 2023 at 3:45 p.m. Pacific Time (6:45 p.m. Eastern Time).

GoodRx to Present at the 41st Annual J.P. Morgan Healthcare Conference

Goodrx Holdings Inc (NASDAQ: GDRX) ended nearly 20% up on Thursday after a Citi analyst issued a bullish note on the California-based telemedicine company. Goodrx stock has upside to $7.0 a share Daniel Grosslight assumed coverage of the healthcare stock this morning with a “buy” rating and a $7.

This telemedicine stock could shoot up 60%: Citi

The company, which focuses on delivering prescription drug discounts, has struggled this year.

Why Shares of GoodRx Holdings Fell 18.7% Lower This Week

Netflix

These businesses could perform much better next year.

2 Growth Stocks Down More Than 50% From Their Highs That Could Be Hot Buys for 2023

The consensus price target hints at a 97.4% upside potential for GoodRx Holdings, Inc. (GDRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think GoodRx Holdings, Inc. (GDRX) Could Surge 97%: Read This Before Placing a Bet

LHC Group

GDRX vs. LHCG: Which Stock Is the Better Value Option?

GDRX or LHCG: Which Is the Better Value Stock Right Now?

Revenue continued to slide at the healthcare company.

Why GoodRx Stock Was Plunging Today

GoodRx Holdings, Inc. (NASDAQ:GDRX ) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET Company Participants Whitney Notaro – Vice President-Investor Relations Doug Hirsch – Co-Founder and Co-Chief Executive Officer Trevor Bezdek – Co-Founder and Co-Chief Executive Officer Karsten Voermann – Chief Financial Officer Conference Call Participants Jailendra Singh – Truist Michael Cherny – Bank of America Eric Sheridan – Goldman Sachs Doug Anmuth – JPMorgan Stephanie Davis – SVB Securities Craig Hettenbach – Morgan Stanley Jonathan Yong – Credit Suisse Sandy Draper – Guggenheim Partners Steve Valiquette – Barclays Stan Berenshteyn – Wells Fargo Scott Schoenhaus – KeyBanc Robert Simmons – D.A. Davidson Operator Ladies and gentlemen, and thank you for standing by.

GoodRx Holdings, Inc. (GDRX) Q3 2022 Earnings Call Transcript

GoodRx Holdings, Inc. (GDRX) delivered earnings and revenue surprises of 75% and 1.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

GoodRx Holdings, Inc. (GDRX) Beats Q3 Earnings and Revenue Estimates

GoodRx Reports Third Quarter 2022 Results

New Report from GoodRx Shows Positive Impact of Giving Pharmacists the Power to Prescribe

GoodRx Holdings, Inc. (GDRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for GoodRx Holdings Stock (GDRX)